Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
119M
-
Number of holders
-
205
-
Total 13F shares, excl. options
-
129M
-
Shares change
-
+187K
-
Total reported value, excl. options
-
$1.79B
-
Value change
-
+$16.1M
-
Put/Call ratio
-
0.45
-
Number of buys
-
96
-
Number of sells
-
-94
-
Price
-
$13.93
Significant Holders of Arcutis Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (ARQT) as of Q4 2024
243 filings reported holding ARQT - Arcutis Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2024.
Arcutis Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (ARQT) has 205 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 129M shares
.
Largest 10 shareholders include JENNISON ASSOCIATES LLC (12.3M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (11.4M shares), Rubric Capital Management LP (11M shares), BlackRock, Inc. (9.15M shares), Frazier Life Sciences Management, L.P. (8.79M shares), Polar Capital Holdings Plc (7.38M shares), VANGUARD GROUP INC (6.44M shares), STATE STREET CORP (4.95M shares), MORGAN STANLEY (4.24M shares), and GILDER GAGNON HOWE & CO LLC (3.9M shares).
This table shows the top 205 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.